

Primary Health Properties

Interim results

Positively as expected

As may be expected from Primary Health Properties' (PHP) robust business model and the essential role that its assets play in supporting the delivery and modernisation of primary healthcare provision in both the UK and Ireland, H121 results provided few surprises. The existing portfolio performed well, and while acquisition activity was light amid a highly competitive investment market, progress was made with rent reviews and asset management projects, forward-funded developments and the recently acquired direct development pipeline.

Year end	Net rental income (£m)	Adj earnings* (£m)	Adj EPS** (p)	Adj EPRA*** NTA/share (p)	DPS (p)	P/NTA (x)	Yield (%)
12/19	115.7	59.7	5.5	107.9	5.60	1.56	3.3
12/20	131.2	73.1	5.8	112.9	5.90	1.49	3.5
12/21e	136.1	82.3	6.2	117.0	6.20	1.44	3.7
12/22e	140.5	85.8	6.5	120.5	6.40	1.39	3.8

Note: *Excludes valuation movements, amortisation of fair value adjustment to acquired debt and other exceptional items. **Non-diluted. ***Net tangible assets; adjusts for fair value of derivative interest rate contracts and convertible bond, deferred tax and fair value adjustment on acquired debt.

H121 driven by organic growth and lower costs

H121 adjusted earnings increased by 13% to £40.7m or 3.1p per share, driven by organic rental growth, reduced borrowing cost, and expense savings related to management internalisation (estimated to reach £4.0m pa). The EPRA cost ratio fell to a sector-leading 9.0%. While a competitive investment market restricted acquisitions, it boosted valuations. Adjusted NTA per share rose 2.2% to 115.4p and including DPS paid of 3.1p (+5.1%) the adjusted NTA total return was 5.0%. We expect investment commitments to pick up in H221 and our forecasts are little changed other than an increase in adjusted NTA.

Well placed to support health service investment

The long-term need for primary healthcare facilities is driven by demographic trends and is relatively unaffected by economic conditions. In both the UK and Ireland, populations are growing and ageing, with more complex healthcare needs. There is no sign that the pandemic has reduced the need for primary care facilities, despite the use of online and telephone appointments, particularly for front-line triage. Indeed, the need for modern, integrated, local primary healthcare facilities is becoming yet more pressing to relieve the pressure being placed on hospitals. PHP is well-placed to help meet this need for investment and grow further; it has c £335m of available funding headroom and a strong pipeline of identified potential acquisitions, asset management projects and developments.

Valuation: Securely growing income

PHP's valuation is driven by income visibility with good prospects for growth: long and substantially upwards-only leases, 90% backed directly or indirectly by government bodies, with little exposure to the economic cycle or fluctuations in occupancy. The FY21e DPS of 6.2p represents a yield of 3.7%, with good prospects for DPS growth, fully covered by adjusted earnings, and supports the premium to NAV.

Real estate

9 August 2021

Price 166p
Market cap £2,201m

Net debt (£m) at 30 June 2021	1,085
Net LTV at 30 June 2021	40.9%
Shares in issue	1,330.2m
Free float	97%
Code	PHP
Primary exchange	LSE
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	3.8	10.7	6.8
Rel (local)	3.1	8.7	(12.3)
52-week high/low	166.8p	138.8p	

Business description

Primary Health Properties is a long-term investor in primary healthcare property in the UK and the Republic of Ireland. Assets are mainly long-let to GPs and the NHS or HSE, organisations backed by the UK and Irish governments, respectively. The tenant profile and long average lease duration provide an exceptionally secure rental income stream.

Next events

Q321 DPS paid	20 August 2021
---------------	----------------

Analyst

Martyn King +44 (0)20 3077 5745

financials@edisongroup.com
[Edison profile page](#)

Primary Health Properties is a research client of Edison Investment Research Limited

H121 performance ‘positively’ as expected

As may be expected from the robustness of PHP’s business model and the essential nature that its assets play in supporting the delivery and modernisation of primary healthcare provision in both the UK and Ireland, the H121 results provided few surprises. With 90% of rental income funded by government bodies, more than 99% of H121 rents have been collected and vacancy remains minimal (occupancy of 99.7%). Dividend payments have been unaffected by the pandemic and PHP is well into its 25th year of uninterrupted DPS growth. PHP has been actively working with the health services and general practitioner (GP) tenants to help them better utilise group properties for deployment in the front line of the current health crisis and has meanwhile continued to actively deploy capital, in many cases bringing additional new-build, high-quality facilities to the sector. H121 acquisition activity was light amid a highly competitive investment market, but the pipeline of investment opportunities has continued to grow while progress continued with rent reviews and asset management projects, forward-funded developments and the recently acquired direct development pipeline. Meanwhile, the successfully completed internalisation of the group’s management structure (in January 2021) began to deliver immediate cost savings, expected to be c £4.0m on an annual basis, further reducing the EPRA cost ratio, which is now the lowest within the UK real estate investment trust (REIT) sector.

The highlights of the interim results were:

- H121 adjusted earnings (EPRA earnings further adjusted to exclude the non-cash positive amortisation on the fair value adjustment on the MedicX fixed rate debt at acquisition) increased by £4.7m or 13% to £40.7m (H120: £36.0m). Growth was driven by the cost savings related to management internalisation, rental growth and a reduction in the cost of borrowing.
- Administrative costs were £1.4m (c 25%) lower at £4.3m compared with £5.7m in H120 and the EPRA cost ratio reduced further to 9.0% (FY20: 11.9%).
- Included in IFRS earnings, the net valuation surplus of £66.9m was driven by yield compression, rent reviews and asset management projects.
- IFRS earnings also included £37.0m of one-off costs in relation to the management internalisation (exceptional termination payment, impairment of goodwill and transaction costs), a small negative fair value adjustment (£0.2m) in respect of interest rate derivatives and the convertible bond, and a £1.5m gain on the amortisation of the fair value adjustment on the MedicX fixed rate debt at acquisition.
- Adjusted EPRA net tangible assets, or NTA, (EPRA NTA adjusted for the negative fair value adjustment on the MedicX fixed rate debt at acquisition) increased by 2.5p or 2.2% to 115.4p during H121 compared with end-FY20 and by 6.3p or 5.8% compared with end-H120. Including DPS paid, the EPRA NTA total return in the period was 5.0%.
- The two quarterly distributions in the period amounted to 3.1p per share, a 5.1% increase compared with H120, and a third quarterly DPS of 1.55p has been declared for Q3 for payment in November. Adjusting for dividends satisfied by scrip share issuance, dividends paid were effectively (99%) covered by adjusted earnings.

Exhibit 1: Summary of H121 financial performance

£m unless stated otherwise	H121	H120	H121/H120	H220
Net rental income	67.7	64.8	4.5%	66.4
Administrative expenses	(4.3)	(5.7)	-24.6%	(5.9)
Performance incentive fee accrual (PIF)	(0.7)	(0.8)	-12.5%	(0.8)
Net finance expense	(22.0)	(22.3)	-1.3%	(22.6)
Basic adjusted earnings*	40.7	36.0	13.1%	37.1
Amortisation of fair value adjustment on acquired debt	1.6	1.5		1.6
Costs/charges relating to acquisition of Nexus	(29.0)	0.0		0.0
Basic EPRA earnings	13.3	37.5		38.7
Property revaluation	66.9	10.5		40.8
Profit on sale of properties	0.0	0.0		0.1
Fair value loss on derivatives	(0.7)	(8.1)		(4.8)
Fair value gain/(loss) on convertible bond	0.5	(0.3)		(2.0)
Costs/charges relating to acquisition of Nexus	(8.0)	0.0		0.0
Tax charge	(0.6)	(0.1)		(0.3)
Basic IFRS earnings	71.4	39.5		72.5
Basic IFRS EPS (p)	5.4	3.2		5.5
Basic EPRA EPS (p)	1.0	3.1		2.9
Basic adjusted EPS (p)	3.1	3.0	3.6%	2.8
DPS (p)	3.10	2.95	5.1%	2.95
Dividend cover**	0.99	1.00		0.99
Adjusted EPRA NAV per share (p)***	115.4	109.1	5.8%	112.9
EPRA NAV total return	5.0%	3.8%		6.2%
Investment portfolio (bn)	2.66	2.51		2.58
Portfolio net initial yield (NIY)	4.70%	4.86%		4.81%
Net LTV	40.9%	45.8%		41.0%
EPRA cost ratio	9.0%	11.6%		12.3%

Source: PHP data. Note: *Adjusted earnings excludes valuation movements, amortisation of acquired fixed rate debt revaluation and other exceptional items. **Dividend cover is EPRA earnings as a percentage of dividends declared. ***Adjusted EPRA NAV excludes fair value movements in derivative interest rate contracts and convertible bonds, acquired fixed rate debt revaluation and deferred tax.

Portfolio update: Continuing to invest in asset quality and rental growth

At 30 June 2021, PHP's portfolio of 514 assets was externally valued at £2.65bn with a contracted rent roll of £136.1m. The £0.9m growth in the rent roll during H121 was predominantly organic and includes a negative £0.6m FX translation impact in respect of the Irish portfolio. Rent reviews and asset management projects added £1.3m, while PHP's disciplined approach to acquisitions was reflected in an unusually low contribution from acquisitions, with just one standing asset added in the period, contributing £0.2m. PHP highlights a lack of availability of suitable product in H121 and a highly competitive market reflected in strong pricing. It notes the importance of not only identifying the right assets but acquiring them at the right price. The strength of market competition for assets was reflected in the valuation of PHP's own portfolio, which generated a valuation surplus of £66.9m, or 2.6%, driven primarily by compression in the net initial yield (from 4.81% in December to 4.70%) in addition to rental growth.

The 19 assets in Ireland, including two under development, account for c 8% of the total by valuation, and with a focus on purpose-built, larger, multi-disciplinary medical centres their average lot size (on a fully developed basis) of c £11.4m enhances the overall portfolio average lot size of £5.2m.

With 90% of contracted rental income paid directly or indirectly by the UK and Irish governments, and the balance primarily by co-located pharmacies, covenant strength is exceptionally strong and, given the nature of the assets, vacancy is minimal (99.7% occupancy). More than 99% of H121 rents in both the UK and Ireland have been collected and Q321 is following a similar trend, with 97% already collected by 26 July with the balance expected shortly after. The weighted average

unexpired lease term (WAULT) is 11.8 years and only c 5% (£6.7m of rent roll) expires over the next three years. Of this, 75% is subject to a planned asset management initiative (see below) or terms have been agreed to renew the lease.

Exhibit 2: Portfolio summary as at 30 June 2020

	H121	2020	2019
Total number of properties	514	513	488
Of which properties in Ireland	19	18	16
Of which under development	3*	6	6
Investment portfolio value	£2.65bn	£2.58bn	£2.41bn
Contracted rent roll	£136.1m	£135.2m	£127.7m
Net initial yield	4.70%	4.81%	4.86%
Average lot size	£5.2m	£5.0m	£4.9m
Average WAULT	11.8 years	12.1 years	12.8 years
Occupancy	99.7%	99.6%	99.5%

Source: PHP. Note: *Eastbourne Primary Care Centre in East Sussex completed in July 2021.

The portfolio provides a stream of high-quality recurring income with good potential for further growth through acquisitions of standing assets and pre-let developments, development completions, asset management and rental growth.

Strong investment pipeline driven by underlying demand

The key drivers of medium-term demand for investment in primary healthcare properties are demographic, including a growing population of elderly with increasingly complex medical needs, combined with the drive to shift healthcare delivery out of expensive and inflexible hospitals. The COVID-19 pandemic has increased the numbers of delayed and deferred hospital appointments, accelerating the migration out of hospitals, and increasing the demand for primary healthcare services despite the use by GPs of internet and telephone for initial consultations.

Although completed acquisition activity was low in H121, PHP continued to make progress with forward-funded developments, asset management projects and the recently acquired direct development pipeline as well as growing its pipeline of acquisition opportunities. While valuation yields have tightened, the accretive nature of continued acquisition-led growth has been maintained by continued reductions in marginal funding costs and administrative cost efficiencies. The immediate pipeline of potential acquisition opportunities totals c £195m across the UK (£87m) and Ireland (£108m), of which c £155m is in legal due diligence. A number of other investment and forward-funded development opportunities are being progressed.

Direct and forward-funded developments

Newly developed, pre-let, purpose-built assets provide access to high-quality assets with new, long leases of typically 25 years. PHP has always engaged in the forward funding of developments, acquiring the pre-let assets on completion, but with the acquisition of Nexus added a direct development business, Nexus Developments, and pipeline of opportunities. These can now be undertaken by PHP, on a pre-let basis, utilising its own substantial balance sheet, with the prospect of enhanced yields. On acquisition, Nexus Developments had an £80m pipeline of direct development opportunities in the UK, at varying stages of progression. The number of 'live' projects has since increased from two (with an estimated capital value of c £10m) to four (£21m), two of which are expected to be on-site by early 2022. In addition, PHP continues to bring forward a wider medium-term pipeline across 17 projects, that now amounts to c £125m.

Exhibit 3: Four directly developed primary care centres progressing towards a start on-site

	Estimated start date	Development cost	BREEAM* rating	WAULT
Lincolnshire	Q421	£4.0m	Excellent	25 years
West Sussex	Q122	£6.7m	Excellent	25 years
South London	Q222	£5.6m	Excellent	25 years
North London	Q323	£4.6m	Very good (shell fit-out)	25 years
Total		£20.9m		

Source: PHP. *Building Research Environmental Assessment Method

At the start of FY21 there were six forward-funded development projects on-site, of which four, with an aggregate net development cost of £20.1m, completed during H121, on time and on budget. Two larger projects, both in Ireland, with an aggregate net development cost of £21.4m, remain on-site and are scheduled to complete in Q122.

Exhibit 4: Two forward-funded developments remain on-site, both in Ireland

	Expected completion	Net development cost	Costs to complete
Arklow, County Wicklow	Q122	£15.4m (€18.0m)	£8.6m (€10.0m)
Enniscorthy, County Wexford	Q122	£10.8m (€12.6m)	£8.2m (€9.6m)
Total		£26.2m	£16.8m

Source: PHP. Note: Eastbourne Primary Care Centre in East Sussex completed in July 2021.

Asset management

Asset management projects, such as property extensions, upgrades and refurbishments, are an attractive way of enhancing the quality of the portfolio and avoiding obsolescence, at the same time supporting tenants to improve their healthcare delivery, while generating additional rents and supporting lease extensions/regears. Lease extensions (ie increasing the length of the lease) increase the visibility and duration of income and enhance asset valuations. During H121, 17 projects were either completed or continue on-site with an aggregate investment requirement of £10.8m. These will generate c £0.3m of additional rental income but, just as importantly, will extend the WAULT on those properties back to 21 years. A further c 100 projects have either been approved by the PHP board or are in advanced negotiations, requiring an investment of c £46m, potentially generating an additional £1.4m of rental income and similarly extending WAULT on those premises back to an average of 22 years.

Continuing rental growth


Rental growth continued in H121, adding c £1.0m to the rent roll, although the 1.5% average uplift on completed rent reviews was slightly lower than the 1.8% achieved in FY20 and 1.9% in FY19. The pandemic has had a dampening impact on pharmacy rent growth and inflation remained at low levels, while the open market rent reviews completed in the period included relatively few in London and the South-East, which tend to be higher. PHP indicated that it expects a higher rate of growth in H221 and that over the next couple of years it expects rent growth to approach the c 2% long-term trend. The average uplift on completed open market rent reviews (69% of total rents¹) were at an average 1.0% pa uplift compared with 1.3% in FY20. A substantial number of additional open market rent reviews that have been agreed in principle but not completed are expected to add c £1.2m to the rent roll, representing an average uplift of 1.2% pa.

An acceleration in open market rent reviews, typically undertaken every three years, would be significantly positive for PHP and several factors have the potential to drive this. Across the market there is evidence that open market rent reviews have failed to sufficiently capture the strong rise in land and build costs in recent years. If much needed new capacity to support the modernisation of the NHS is going to be delivered, the rents available will need to justify the investment. The

¹ Index-linked rent uplifts (25% of total rents) were at an average 2.2% and fixed uplifts (6% of total rents) were at an average 2.7% in H121.

increasing delivery of new, purpose-built premises is providing ample 'evidence', and a positive benchmark, for the district valuers with whom all rent reviews must be agreed. Increased regulatory requirements, including in respect of energy efficiency, are also driving 'specification creep', which provides further support for rent levels. Meanwhile, the requirement to reach agreement with the district valuer has contributed to a substantial backlog of outstanding rent reviews (619 tenancies representing £83m of rents) with the potential to enhance rent roll when completed.

Exhibit 5: Rental growth history (average annualised uplift on completed reviews in year)



Source: PHP data, Edison Investment Research

Financials and estimates

Our forecast for further dividend growth is unchanged, which we expect to be fully covered despite a slight reduction in our adjusted earnings forecasts due to slower than previously expected portfolio investment. Reflecting the H121 growth in asset valuations, driven primarily by yield tightening, our forecasts for NAV/EPRA NTA per share are increased.

Exhibit 6: Summary of forecast changes

	Net rental income (£m)			Adjusted earnings (£m)			Adjusted EPS (p)			DPS (p)			Adj. EPRA NTAPS (p)		
	Old	New	% chge	Old	New	% chge	Old	New	% chge	Old	New	% chge	Old	New	% chge
12/21e	137.4	136.1	-1.0	82.8	82.3	-0.6	6.3	6.2	-0.9	6.2	6.2	0.0	113.8	117.0	3.2
12/22e	142.4	140.5	-1.3	86.6	85.8	-1.0	6.5	6.5	-1.0	6.4	6.4	0.0	117.3	120.5	3.2

Source: Edison Investment Research

Forecasts in detail

The key underlying assumptions driving our FY21 and FY22 forecasts include:

- New investment commitments of £75m in H221 and £120m in FY22, a mix of fully let completed assets and forward funding commitments in both the UK and Ireland. Our assumed FY21 commitment is reduced from £120m previously and reflecting the strength of investment demand we also assume a lower acquisition yield (a blended 4.7% compared with c 4.8% previously), similar to the current portfolio net initial yield.
- We assume a blended average 1.8% pa like-for-like rental growth.
- For FY21 we have built in the c £4.0m of annualised cost savings related to the internalisation of the management structure, with modest growth in FY22.
- We expect asset growth to be financed out of cash resources in FY21 with further debt drawn down in FY22, although the impact on finance costs is mitigated by low marginal cost of funding.
- We make no assumption of changes in market valuation yields (either up or down) and reflect the assumed rental growth in gross revaluation gains, partly offset by assumed acquisition costs. We estimate that a 0.1% decrease in the portfolio net initial yield would increase FY21e

EPRA NAV per share by c 4p, with a 0.1% increase in net initial yield having a similar negative impact.

Significant funding headroom and refinancing opportunities.

PHP's strong balance sheet position leaves it well placed to fund investment-led growth, while refinancing opportunities remain for a further reduction in the average cost of borrowing.

The end-H121 loan to value (LTV) ratio of 40.9% (or 35.2% assuming conversion of the outstanding convertible bonds) was comfortably within the target gearing range with an upper limit of 50%. Compared with the more cyclical mainstream commercial property sector, LTVs for primary healthcare investment are typically higher, recognising the highly secure, long-term nature of the cash flows, and reflected in the end-H121 interest cover ratio of 3.2 times. End-H121 funding headroom (cash plus undrawn debt) available for investment was £335.0m.

The average cost of debt at end-H121 was 3.4% (end-FY20: 3.5%) and on a fully drawn basis would fall to 3.1%, reflecting the low marginal cost of borrowing (1.7%). Although the weighted average maturity of the debt portfolio is a long 7.0 years, there are certain facilities that mature by end 2023 where, based on current market conditions, PHP is hopeful of reducing the average cost of debt further. It is already engaged in positive discussions with lenders and it hopes to be able to realise funding cost efficiencies before the end of 2021, well before the actual maturities. We have not assumed this in our forecasts.

Interest rate risk is well managed, with 100% either fixed rate or hedged. Unfettered assets of £110.5m at end-H121 provide significant flexibility in the utilisation of the debt facilities.

Exhibit 7: Key debt metrics

	30 June 2021	31 December 2020
	H120	2020
Average cost of drawn debt	3.4%	3.5%
Average cost of debt - fully drawn	3.1%	3.1%
Loan to value (LTV)	40.9%	41.0%
Interest cover	3.2 times	2.9 times
Weighted average debt maturity	7.0 years	7.6 years
Total debt facilities	£1,449.1m	£1,456.8m
Total drawn debt	£1,157.7m	£1,159.3m
o/w drawn secured debt	£1,007.7m	£1,009.3m
o/w drawn unsecured debt	£150.0m	£150.0m
Total undrawn facilities and cash available	£335.0m	£361.5m
Unfettered assets	£110.5m	£88.4m

Source: PHP

Valuation

Historical returns on primary healthcare assets have been higher than other sectors of the UK commercial property market, with a lower level of volatility. This has been a function of strong healthcare fundamentals, secure and more resilient income, and more muted yield shifts through the property cycle.


Over the past five and a half years (from end-FY15 to end-H121), PHP generated an EPRA NAV total return of 66.1% or a compound 9.7% pa (dividends added back but not reinvested). Dividends paid have accounted for a little more than half of the return, with capital returns contributing the balance including the impact of asset management, rental growth and yield tightening.

Exhibit 8: EPRA net tangible asset (NTA) total return history

	2016	2017	2018	2019	2020	H121	5.5-years
Opening EPRA NTA (p)	87.7	91.1	100.7	105.1	107.9	112.9	87.7
Closing EPRA NTA (p)	91.1	100.7	105.1	107.9	112.9	115.4	115.4
Dividends paid in period (p)	5.13	5.25	5.40	5.60	5.90	3.10	30.4
Income return	5.8%	5.8%	5.4%	5.3%	5.5%	2.7%	34.6%
Capital return	3.8%	10.5%	4.4%	2.7%	4.6%	2.2%	31.5%
NTA total return	9.7%	16.3%	9.8%	8.0%	10.1%	5.0%	66.1%
Compound annual average return							9.7%

Source: PHP data, Edison Investment Research

The targeted FY20 DPS of 6.2p (+5.1% vs FY20), for which the first three quarterly payments have been made or declared, represents a prospective 3.7% dividend yield and we forecast dividends to be fully covered by adjusted earnings, with good potential for further growth.

Exhibit 9: PHP is now in its 25th year of unbroken DPS growth


Source: PHP data

Importantly, PHP's income and dividend paying capacity is backed by a secure, upwards only rent profile, c 90% funded directly or indirectly by the NHS in the UK or HSE in Ireland. Given the nature of this income stream it is tempting to draw comparison with its dividend yield and the generic yield on 10-year gilts, which increased to 0.9% earlier in 2021 on rising concern about inflation but have since fallen to c 0.5%. It is PHP's secure and growing income profile that is the driver of the share price and that provides the support for a continuing valuation premium to EPRA NAV (currently 1.4x), in our view.

In Exhibit 10 we show the key valuation and performance metrics for PHP and a group of its closest peers, including Assura, another investor in primary healthcare assets, care home investors (Impact and Target) and social housing investors (Civitas, Secure Residential Income and Triple Point). Average share price performance for the group has been ahead of the wider UK equity market and broad UK property sector over the past three years. PHP's three-year share price performance is well above the average and the strongest of the peer group. The peer group (and PHP) share price performance has continued to be positive over the past year but has been eclipsed by a rebound in the share price performance of many companies that had been harder hit by the pandemic. In valuation terms, compared with the average of the group, PHP continues to trade with a lower dividend yield and higher P/NAV, which we believe can be attributed to investor recognition of the strength of the tenant covenant, its strong balance sheet and opportunities for growth, and the strength of free cash flow, supported by its lower cost ratio.

Exhibit 10: Peer comparison

	Price (p)	Market cap. (£m)	P/NAV* (x)	Yield** (%)	Share price performance			
					1 month	3 months	12 months	3 year
Assura	79	2,113	1.38	3.6	4%	8%	-2%	40%
Civitas Social Housing	119	751	1.11	4.5	5%	5%	7%	17%
Impact Healthcare	117	376	1.07	5.4	2%	5%	16%	15%
Residential Secure Income	107	179	0.99	4.8	-2%	6%	15%	11%
Target Healthcare	124	573	1.15	5.4	6%	6%	14%	9%
Triple Point Social Housing	111	445	1.04	4.7	5%	5%	7%	5%
Average			1.12	4.7	3%	6%	9%	16%
Primary Health Properties	166	2,201	1.44	3.6	4%	11%	7%	43%
UK property sector index	1,923				7%	11%	29%	7%
UK equity market index	4,089				1%	1%	22%	-3%

Source: Company data, Edison Investment Research, Refinitiv. Note: *Based on last reported EPRA NAV. **Based on 12-month trailing dividends declared. Prices at 6 August 2021.

Exhibit 11: Financial summary

Year end 31 December (£m)	2018	2019	2020	2021e	2022e
PROFIT & LOSS					
Net rental income	76.4	115.7	131.2	136.1	140.5
Administrative expenses	(9.9)	(12.3)	(13.2)	(9.6)	(9.8)
EBITDA	66.5	103.4	118.0	126.5	130.7
Net result on property portfolio	36.1	49.8	51.4	88.0	45.1
Exceptional items related to corporate acquisition	0.0	(148.6)	0.0	(37.0)	0.0
Operating profit before financing costs	102.6	4.6	169.4	177.5	175.8
Finance income	0.1	1.4	1.2	0.8	1.0
Finance expense	(29.8)	(42.6)	(43.0)	(41.8)	(42.8)
Net finance expense	(29.7)	(41.2)	(41.8)	(41.0)	(41.8)
Net other income/expense	1.4	(33.6)	(15.2)	(0.2)	0.0
Profit Before Tax	74.3	(70.2)	112.4	136.3	134.1
Tax	0.0	(1.1)	(0.4)	(0.6)	0.0
Profit After Tax (FRS 3)	74.3	(71.3)	112.0	135.7	134.1
Adjusted for the following:					
Net gain/(loss) on revaluation	(36.0)	(48.4)	(51.3)	(88.0)	(45.1)
Profit on disposal	(0.1)	(1.4)	(0.1)	0.0	0.0
Fair value gain/(loss) on derivatives & convertible bond	(1.4)	33.6	15.2	0.2	0.0
Exceptional items related to corporate acquisition	0.0	138.4	0.0	8.0	0.0
Deferred tax	0.0	1.1	0.4	0.6	0.0
EPRA earnings	36.8	52.0	76.2	56.5	89.0
Exceptional item		10.2	0.0	29.0	0.0
Amortisation of fair value adjustment to acquired debt		(2.5)	(3.1)	(3.2)	(3.2)
Adjusted EPRA earnings	36.8	59.7	73.1	82.3	85.8
Period end number of shares (m)	769.1	1,216.3	1,315.6	1,330.2	1,330.2
Average Number of Shares Outstanding (m)	708.6	1,092.0	1,266.4	1,327.9	1,327.0
Fully diluted average number of shares outstanding (m)	732.7	1,138.5	1,368.4	1,430.5	1,429.0
Basic IFRS EPS (p)	10.5	(6.53)	8.8	10.2	10.1
Basic adjusted EPRA EPS (p)	5.2	5.5	5.8	6.2	6.5
Diluted adjusted EPRA EPS (p)	5.2	5.4	5.7	6.1	6.3
Dividend per share (p)	5.400	5.600	5.900	6.200	6.400
Dividend cover (Adj. EPRA earnings/dividends paid)	101%	101%	100%	100%	101%
EPRA cost ratio	14.3%	12.0%	11.9%	8.7%	8.7%
BALANCE SHEET					
Non-current assets	1,503.5	2,413.6	2,576.1	2,737.1	2,886.7
Investment properties	1,502.9	2,413.1	2,576.1	2,735.7	2,885.3
Other non-current assets	0.6	0.5	0.0	1.4	1.4
Current Assets	10.5	159.8	121.0	30.1	29.2
Cash & equivalents	5.9	143.1	103.6	15.2	14.3
Other current assets	4.6	16.7	17.4	14.9	14.9
Current Liabilities	(134.5)	(66.0)	(68.1)	(59.0)	(59.0)
Current borrowing	(102.4)	(6.1)	(6.4)	0.0	0.0
Other current liabilities	(32.1)	(59.9)	(61.7)	(59.0)	(59.0)
Non-current liabilities	(591.5)	(1,278.9)	(1,214.6)	(1,217.9)	(1,317.5)
Non-current borrowings	(573.7)	(1,257.8)	(1,206.5)	(1,209.5)	(1,309.1)
Other non-current liabilities	(17.8)	(21.1)	(8.1)	(8.4)	(8.4)
Net Assets	788.0	1,228.5	1,414.4	1,490.3	1,539.4
Derivative interest rate swaps	17.2	13.0	0.1	(1.3)	(1.3)
Change in fair value of convertible bond	3.4	22.7	25.0	24.5	24.5
Other EPRA adjustments	0.0	48.6	45.8	43.0	39.8
Adjusted EPRA net tangible assets (NTA)	808.6	1,312.8	1,485.3	1,556.5	1,602.4
IFRS NAV per share (p)	102.5	101.0	107.5	112.0	115.7
Adjusted EPRA NTA per share (p)	105.1	107.9	112.9	117.0	120.5
CASH FLOW					
Operating Cash Flow	68.5	94.0	118.9	127.6	129.3
Net Interest & other financing charges	(35.1)	(52.9)	(65.9)	(42.1)	(42.2)
Tax	0.0	0.0	0.0	0.0	0.0
Acquisitions/disposals	(101.9)	(47.4)	(102.8)	(82.3)	(103.1)
Net proceeds from issue of shares	111.0	97.6	136.8	(0.1)	0.0
Debt drawn/(repaid)	(5.6)	110.5	(58.4)	4.6	100.0
Equity dividends paid (net of scrip)	(34.7)	(54.4)	(69.1)	(77.5)	(84.9)
Other cash movements and FX	0.6	(11.9)	1.6	(19.2)	0.0
Net change in cash	2.1	137.2	(39.5)	(88.5)	(0.9)
Opening cash & equivalents	3.8	5.9	143.1	103.6	15.1
Closing net cash & equivalents	5.9	143.1	103.6	15.1	14.2
Debt as per balance sheet	(676.1)	(1,263.9)	(1,212.9)	(1,209.5)	(1,309.1)
Convertible bond fair value adjustment	3.4	22.7	25.0	24.4	24.4
Unamortised borrowing costs	(6.4)	(14.6)	(13.8)	(11.8)	(9.0)
Acquired debt fair value a	0.0	45.4	42.4	39.2	36.0
Net debt	(673.2)	(1,067.3)	(1,055.7)	(1,142.6)	(1,243.5)
Net LTV	44.8%	44.2%	41.0%	41.7%	43.0%

Source: PHP historical data, Edison Investment Research forecasts

General disclaimer and copyright

This report has been commissioned by Primary Health Properties and prepared and issued by Edison, in consideration of a fee payable by Primary Health Properties. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2021 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
1185 Avenue of the Americas
3rd Floor, New York, NY 10036
United States of America

Sydney +61 (0)2 8249 8342
Level 4, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia